On 11/16/2009, Biofield Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

On 08/14/2009, Biofield Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Biofield Corp. announced that it has shipped the initial order of its proprietary Biofield Diagnostic System for the early detection of breast cancer units, to an exclusive distributor representing the Mexican, Central and Latin American markets. The distributor, MacKay Health Systems, acquired the rights to Mexico and various Central & Latin American countries via an exclusive distribution agreement it entered into with MacKay Innotech LTD. Under the terms of distribution agreement, MHS will pay MHK a non-refundable licensing fee of $1 million dollars and 10% Royalty of Gross Revenues. Terms require the distributor to purchase a minimum number of units per quarter, per country. The specific countries are: Aruba, Belize, Costa Rica, Dominican Republic, El Salvador, Guadeloupe, Guatemala, Haiti, Honduras, Martinique, Mexico, Netherland Antilles, Nicaragua, Puerto Rico. Saint Martin and Saint Pierre & Miquelon. The company has, this week, shipped the initial order, as per the terms of the agreement. Regular recurring shipments are expected to follow. The company, which recently completed its transformation from a medical technology company which solely developed and distributed its own proprietary technology (the BDS unit) to one that also has and seeks to acquire other, primarily, noninvasive diagnostic medical devices to assist in detecting and preventing cancer and other illnesses.